Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101


Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.

Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.

Cancer Res Treat. 2018 Oct 1. doi: 10.4143/crt.2018.375. [Epub ahead of print]


Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.

Kouvaraki MA, Korapati AL, Rassidakis GZ, Tian L, Zhang Q, Chiao P, Ho L, Evans DB, Claret FX.

Cancer Res. 2006 Sep 1;66(17):8581-9.


Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma.

Pan Y, Zhang Q, Tian L, Wang X, Fan X, Zhang H, Claret FX, Yang H.

Cancer Res. 2012 Apr 1;72(7):1890-900. doi: 10.1158/0008-5472.CAN-11-3472. Epub 2012 Feb 20.


Decreased expression and prognostic role of cytoplasmic BRSK1 in human breast carcinoma: correlation with Jab1 stability and PI3K/Akt pathway.

Wang H, Liu XB, Chen JH, Wang QQ, Chen JP, Xu JF, Sheng CY, Ni QC.

Exp Mol Pathol. 2014 Oct;97(2):191-201. doi: 10.1016/j.yexmp.2014.07.012. Epub 2014 Jul 16.


Inverse expression of Jun activation domain binding protein 1 and cell cycle inhibitor p27Kip1: influence on proliferation in hepatocellular carcinoma.

Berg JP, Zhou Q, Breuhahn K, Schirmacher P, Patil MA, Chen X, Schäfer N, Höller TT, Fischer HP, Büttner R, Gütgemann I.

Hum Pathol. 2007 Nov;38(11):1621-7. Epub 2007 Jul 24.


Jab1 is overexpressed in human breast cancer and is a downstream target for HER-2/neu.

Hsu MC, Chai CY, Hou MF, Chang HC, Chen WT, Hung WC.

Mod Pathol. 2008 May;21(5):609-16. doi: 10.1038/mpath.2008.23. Epub 2008 Feb 8.


Src as a Therapeutic Target in Biliary Tract Cancer.

Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.

Mol Cancer Ther. 2016 Jul;15(7):1515-24. doi: 10.1158/1535-7163.MCT-16-0013. Epub 2016 Apr 22.


Cytoplasmic localization of Jab1 and p27 Kip1 might be associated with invasiveness of papillary thyroid carcinoma.

Ahn J, Hong SA, Lee SE, Kim J, Oh YS, Park SJ, Chung YJ.

Endocr J. 2009;56(5):707-13. Epub 2009 May 20.


[Molecular mechanism of the inhibitory effect of retinoic acid-induced gene G protein on tumor cell proliferation].

Li D, Lou YJ, Xiao S, Pan XR, Jia PM, Tong JH.

Zhonghua Yi Xue Za Zhi. 2008 Jan 8;88(2):110-3. Chinese.


The green tea catechin epigallocatechin gallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells.

Mayr C, Wagner A, Neureiter D, Pichler M, Jakab M, Illig R, Berr F, Kiesslich T.

BMC Complement Altern Med. 2015 Jun 23;15:194. doi: 10.1186/s12906-015-0721-5.


HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells.

Hsu MC, Chang HC, Hung WC.

Endocr Relat Cancer. 2007 Sep;14(3):655-67.


JAB1 and phospho-Ser10 p27 expression profile determine human hepatocellular carcinoma prognosis.

Wang Y, Yu YN, Song S, Li TJ, Xiang JY, Zhang H, Lu MD, Ji F, Hu LQ.

J Cancer Res Clin Oncol. 2014 Jun;140(6):969-78. doi: 10.1007/s00432-014-1646-y. Epub 2014 Mar 27.


The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.

Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC Jr.

J Natl Cancer Inst. 2011 Sep 21;103(18):1403-22. doi: 10.1093/jnci/djr280. Epub 2011 Aug 2.


Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1).

Kouvaraki MA, Rassidakis GZ, Tian L, Kumar R, Kittas C, Claret FX.

Cancer Res. 2003 Jun 1;63(11):2977-81.


Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.

Esteva FJ, Sahin AA, Rassidakis GZ, Yuan LX, Smith TL, Yang Y, Gilcrease MZ, Cristofanilli M, Nahta R, Pusztai L, Claret FX.

Clin Cancer Res. 2003 Nov 15;9(15):5652-9.


The Relevance of Women's Diseases, Jun Activation-domain Binding Protein 1 (JAB1) and p27(kip1).

Kim M, Kim TH, Lee HH.

J Menopausal Med. 2016 Apr;22(1):6-8. doi: 10.6118/jmm.2016.22.1.6. Epub 2016 Apr 26. Review.


Depletion of Jab1 inhibits proliferation of pancreatic cancer cell lines.

Fukumoto A, Tomoda K, Yoneda-Kato N, Nakajima Y, Kato JY.

FEBS Lett. 2006 Oct 30;580(25):5836-44. Epub 2006 Sep 27.


The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.

Tomoda K, Kato JY, Tatsumi E, Takahashi T, Matsuo Y, Yoneda-Kato N.

Blood. 2005 Jan 15;105(2):775-83. Epub 2004 Sep 7.


Stat3 and CCAAT/enhancer binding protein beta (C/EBP-beta) regulate Jab1/CSN5 expression in mammary carcinoma cells.

Shackleford TJ, Zhang Q, Tian L, Vu TT, Korapati AL, Baumgartner AM, Le XF, Liao WS, Claret FX.

Breast Cancer Res. 2011 Jun 20;13(3):R65. doi: 10.1186/bcr2902.


Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas.

Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H.

Oncology. 2003;65(4):355-62.


Supplemental Content

Support Center